FDA Moves to Permanently Exclude Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List

In a Federal Register notice published on 1 May 2026, the U.S. Food and Drug Administration proposed a formal finding that there is no clinical need to include semaglutide, tirzepatide and liraglutide on the section 503B bulk drug substances list. The proposal, with a public comment docket open through 29 June 2026, would close the remaining large-scale outsourcing-facility pathway for compounding these incretin peptides from bulk active pharmaceutical ingredient. The agency's safety-rationale page on unapproved GLP-1 products was refreshed on 14 May 2026.

Section 503B of the Federal Food, Drug, and Cosmetic Act lets registered outsourcing facilities compound from bulk drug substances only where the FDA determines a clinical need. The 1 May 2026 notice proposes a no-clinical-need determination for the three leading GLP-1 and GLP-1/GIP peptides. Combined with the earlier removal of these substances from the drug shortage list, the proposal would foreclose industrial-scale compounding of bulk semaglutide, tirzepatide and liraglutide once finalized.

The FDA accompanying safety record cites hundreds of adverse-event reports associated with compounded GLP-1 products and documents fabricated or inaccurate labeling — including product labels naming pharmacies that do not exist or were not involved in production. For a verification platform, the label-integrity finding is the operative detail: it places product identity and documentation provenance at the center of the regulatory record.

The proposal is not final. The public docket is open for comment through 29 June 2026, after which the FDA may issue a final determination. Until then the proposed exclusion is a signal of regulatory direction rather than a settled rule. Researchers tracking supply provenance should treat the period through the second half of 2026 as an active regulatory transition.

In parallel, the FDA issued warning letters dated 31 March 2026 to online sellers operating in the research-chemical space. Gram Peptides was cited for offering products described as Retatrutide and Tirzepatide, and Prime Sciences was cited for selling reconstitution materials alongside peptide products. The warning-letter index was administratively updated on 14 May 2026, keeping these actions inside the current news window.

A recurring theme across the letters is that a research-use-only or not-for-human-consumption label does not, by itself, exempt a product from drug regulation when the surrounding evidence indicates intended human use. The agency treated factors such as bundled reconstitution supplies as part of the intended-use picture. For sourcing diligence, the practical implication is that a disclaimer on a vial is a labeling statement, not a verified attribute of the chemical inside it.

Investigative reporting by ProPublica, with broadcast coverage by PBS NewsHour, has documented concern that loosening compounding restrictions could widen access to peptides with limited clinical characterization, and noted that prior restrictions were associated with an inflow of imported chemicals not subject to U.S. drug-quality standards. These accounts are journalistic context rather than regulatory text, but they frame why provenance and independent characterization are central to the discussion.

The common thread across the 503B proposal, the warning letters and the investigative coverage is documentation integrity: who made a substance, whether the label reflects the contents, and whether identity and purity were measured rather than asserted. None of these questions is answered by a marketing claim. They are answered by analytical data — mass spectrometry for identity, chromatography for purity, and a traceable Certificate of Analysis tied to the specific lot.

Items to watch through mid-2026: the final FDA determination after the comment window, any expansion of the warning-letter pattern to additional sellers, and whether the agency issues further guidance on identity and impurity expectations for synthetic peptides. ChemVerify will track these as chemical-provenance and verification developments.